Data from the PERSEUS trial support the FDA approval of the subcutaneous daratumumab-containing regimen in newly diagnosed multiple myeloma.
Approval Alert | Subcutaneous Daratumumab Combo in Newly Diagnosed Multiple Myeloma
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
3
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
4
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
5